Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy

Summary

The goal of this clinical trial is to learn if neoadjuvant chemotherapy (NAC) affects the accuracy of magnetic resonance imaging (MRI) in staging muscle-invasive bladder cancer (MIBC). This study will also assess how tissue changes induced by NAC impact MRI interpretation. The main questions it aims to answer are: Does NAC compromise the accuracy of MRI in staging MIBC? Does NAC-induced tissue change affect the reliability of MRI in tumor assessment? Researchers will compare MRI staging accuracy in MIBC patients who received NAC to those who went directly to surgery, to see if NAC impacts MRI's diagnostic performance. Participants will: Undergo MRI scanning before surgery Receive either NAC or go directly to surgery, depending on their group assignment Have their MRI results compared to histopathological outcomes after surgery

Eligibility

Inclusion Criteria:

* Patients diagnosed with cT2 urothelial carcinoma of the urinary bladder, according to the TNM classification, who give informed, written consent on participation in the study and approve all its requirements.

Exclusion Criteria:

* Patients who have received pelvic radiotherapy.
* Previous open or laparoscopic pelvic surgery.
* Patients with contraindications to MRI.
* Patients who are unfit for or refuse radical cystectomy.
* Ineligibility to cisplatin.
* squamous differentiation in the histopathology

Conditions2

Interventions1

Related trials

• AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy — Chinese Academy of Sciences
• Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver — Yunnan Cancer Hospital
• Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC — Obstetrics & Gynecology Hospital of Fudan University
• Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) — Rajiv Gandhi Cancer Institute & Research Center, India
• Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy — University Hospital, Rouen
• Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) — First Affiliated Hospital of Zhejiang University
• Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer — Xijing Hospital
• Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) — First Affiliated Hospital of Zhejiang University

Browse More Trials